The preliminary result of EMA inspection of Trogarzo production in SBL｜Institute for Biotechnology and Medicine Industry│IBMI

The preliminary result of EMA inspection of Trogarzo production in SBL

2021-06-03

Return to the news list

｜

Source: TaiMed Biologics

2021-06-02

The European Medicines Agency's (EMA) inspection of TaiMed new AIDS drug Trogarzo for commercial production scale-up in Samsung Biologics (SBL) has been completed on June 1, 2021.

The company was notified by Samsung Biotechnology (SBL) today that there were no critical and major deficiencies in the factory inspection, and it should be smooth.

Previous Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers

Next Taiwanese COVID vaccine developer to present clinical trial results

Return to the news list